Staff Research Physician National Institute on Drug Abuse Intramural Research Program National Institute on Drug Abuse Intramural Research Program, Maryland
Anecdotal reports of the efficacy of semaglutide and other Glucagon-Like Peptide-1 (GLP-1) receptor agonists as medical therapies for obesity have garnered widespread public attention, engendering ethical debates and leading to worldwide drug shortages. This brief presentation will update participants about the National Institute on Drug Abuse Intramural Research Program's ongoing early phase clinical trial studying the exciting possibility of repurposing semaglutide to treat patients with alcohol use disorder.
Learning Objectives:
Learners will be able to:
Evaluate early safety and efficacy data from the National Institute on Drug Abuse Intramural Research Program's ongoing clinical trial studying the safety and efficacy of semaglutide, a GLP-1 receptor agonist, to treat alcohol use disorder.
